Report Information More information from: https ://www.wis eguyreports .com/reports /495871
Burkitt Lymphoma - Pipeline Review, H1 2016 Report / Search Code: WGR495871
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Burkitt Lymphoma - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Burkitt Lymphoma - Pipeline Review, H1 2016’, provides an overview of the Burkitt Lymphoma pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Burkitt Lymphoma, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Burkitt Lymphoma and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Burkitt Lymphoma - The report reviews pipeline therapeutics for Burkitt Lymphoma by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Burkitt Lymphoma therapeutics and enlis ts all their major and minor projects - The report as s es s es Burkitt Lymphoma therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Burkitt Lymphoma Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Burkitt Lymphoma - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics
- Devis e corrective meas ures for pipeline projects by unders tanding Burkitt Lymphoma pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Burkitt Lymphoma Overview 8 Therapeutics Development 9 Pipeline Products for Burkitt Lymphoma - Overview 9 Pipeline Products for Burkitt Lymphoma - Comparative Analys is 10 Burkitt Lymphoma - Therapeutics under Development by Companies 11 Burkitt Lymphoma - Therapeutics under Inves tigation by Univers ities /Ins titutes 12 Burkitt Lymphoma - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Burkitt Lymphoma - Products under Development by Companies 15 Burkitt Lymphoma - Products under Inves tigation by Univers ities /Ins titutes 16 Burkitt Lymphoma - Companies Involved in Therapeutics Development 17 AbbVie Inc. 17 Arvinas , Inc. 18 As traZ eneca Plc 19 Bluebird bio, Inc. 20 Cons tellation Pharmaceuticals , Inc. 21 Immunomedics , Inc. 22 Karyopharm Therapeutics , Inc. 23 Millennium Pharmaceuticals , Inc. 24 Seattle Genetics , Inc. 25 Takeda Pharmaceutical Company Limited 26 Theravectys SA 27 Burkitt Lymphoma - Therapeutics As s es s ment 28 As s es s ment by Monotherapy Products 28 As s es s ment by Target 29 As s es s ment by Mechanis m of Action 31 As s es s ment by Route of Adminis tration 33 As s es s ment by Molecule Type 35 Drug Profiles 37 19-3s - Drug Profile 37 Product Des cription 37 Mechanis m of Action 37 R& D Progres s 37 20-3s - Drug Profile 38 Product Des cription 38 Mechanis m of Action 38 R& D Progres s 38 alis ertib - Drug Profile 39 Product Des cription 39 Mechanis m of Action 39 R& D Progres s 39 ARV-825 - Drug Profile 44 Product Des cription 44 Mechanis m of Action 44 R& D Progres s 44 AZ D-6738 - Drug Profile 46 Product Des cription 46 Mechanis m of Action 46 R& D Progres s 46 bb-2121 - Drug Profile 48 Product Des cription 48 Mechanis m of Action 48 R& D Progres s 48 denintuzumab mafodotin - Drug Profile 49 Product Des cription 49 Mechanis m of Action 49 R& D Progres s 49 E1-3s - Drug Profile 50 Product Des cription 50 Mechanis m of Action 50 R& D Progres s 50 Eps tein-Barr virus vaccine - Drug Profile 51
Product Des cription 51 Mechanis m of Action 51 R& D Progres s 51 ibrutinib - Drug Profile 52 Product Des cription 52 Mechanis m of Action 52 R& D Progres s 52 ixazomib citrate - Drug Profile 59 Product Des cription 59 Mechanis m of Action 59 R& D Progres s 59 Monoclonal Antibody Conjugate to Target CD20 for Leukemia and Burkitt Lymphoma Drug Profile 63 Product Des cription 63 Mechanis m of Action 63 R& D Progres s 63 s elinexor - Drug Profile 64 Product Des cription 64 Mechanis m of Action 64 R& D Progres s 64 SH-7129 - Drug Profile 70 Product Des cription 70 Mechanis m of Action 70 R& D Progres s 70 SH-7133 - Drug Profile 72 Product Des cription 72 Mechanis m of Action 72 R& D Progres s 72 SH-7139 - Drug Profile 73 Product Des cription 73 Mechanis m of Action 73 R& D Progres s 73 Small Molecules to Inhibit BET for Cancer - Drug Profile 75 Product Des cription 75 Mechanis m of Action 75 R& D Progres s 75 Burkitt Lymphoma - Recent Pipeline Updates 76 Burkitt Lymphoma - Dormant Projects 113 Appendix 114 Methodology 114 Coverage 114 Secondary Res earch 114 Primary Res earch 114 Expert Panel Validation 114 Contact Us 114 Dis claimer 115 Lis t of Tables Number of Products under Development for Burkitt Lymphoma, H1 2016 9 Number of Products under Development for Burkitt Lymphoma - Comparative Analys is , H1 2016 10 Number of Products under Development by Companies , H1 2016 11 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 12 Comparative Analys is by Clinical Stage Development, H1 2016 13 Comparative Analys is by Early Stage Development, H1 2016 14 Products under Development by Companies , H1 2016 15 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 16 Burkitt Lymphoma - Pipeline by AbbVie Inc., H1 2016 17 Burkitt Lymphoma - Pipeline by Arvinas , Inc., H1 2016 18 Burkitt Lymphoma - Pipeline by As traZ eneca Plc, H1 2016 19 Burkitt Lymphoma - Pipeline by Bluebird bio, Inc., H1 2016 20 Burkitt Lymphoma - Pipeline by Cons tellation Pharmaceuticals , Inc., H1 2016 21 Burkitt Lymphoma - Pipeline by Immunomedics , Inc., H1 2016 22 Burkitt Lymphoma - Pipeline by Karyopharm Therapeutics , Inc., H1 2016 23 Burkitt Lymphoma - Pipeline by Millennium Pharmaceuticals , Inc., H1 2016 24 Burkitt Lymphoma - Pipeline by Seattle Genetics , Inc., H1 2016 25 Burkitt Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 26 Burkitt Lymphoma - Pipeline by Theravectys SA, H1 2016 27 As s es s ment by Monotherapy Products , H1 2016 28 Number of Products by Stage and Target, H1 2016 30 Number of Products by Stage and Mechanis m of Action, H1 2016 32 Number of Products by Stage and Route of Adminis tration, H1 2016 34 Number of Products by Stage and Molecule Type, H1 2016 36 Burkitt Lymphoma Therapeutics - Recent Pipeline Updates , H1 2016 76 Burkitt Lymphoma - Dormant Projects , H1 2016 113 Lis t of Figures Number of Products under Development for Burkitt Lymphoma, H1 2016 9 Number of Products under Development for Burkitt Lymphoma - Comparative
Analys is , H1 2016 10 Number of Products under Development by Companies , H1 2016 11 Comparative Analys is by Clinical Stage Development, H1 2016 13 Comparative Analys is by Early Stage Products , H1 2016 14 As s es s ment by Monotherapy Products , H1 2016 28 Number of Products by Top 10 Targets , H1 2016 29 Number of Products by Stage and Top 10 Targets , H1 2016 29 Number of Products by Top 10 Mechanis m of Actions , H1 2016 31 Number of Products by Stage and Top 10 Mechanis m of Actions , H1 2016 31 Number of Products by Routes of Adminis tration, H1 2016 33 Number of Products by Stage and Routes of Adminis tration, H1 2016 33 Number of Products by Molecule Types , H1 2016 35 Number of Products by Stage and Molecule Types , H1 2016 35
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349